KADCYLA i.v. subst sèche 160 mg flac
7680628920022
CH-62892
L01FD03
07.16.1.
Reimbursement limitations:
KADCYLA2mono
Traitement adjuvant
Uniquement après accord préalable sur la prise en charge des frais par l'assureur-maladie, …
1 / 3
google
Details
- Product number
- 6289202
- CPT
- -
- Packaging group
- 1
- Unit
- Durchstechflasche(n)
- Composition
- Praeparatio cryodesiccata: trastuzumabum emtansinum 160 mg, saccharum, acidum succinicum, natrii hydroxidum corresp. natrium 2.07 mg, polysorbatum 20, pro vitro.
Articles (1)
Kadcyla 160 mg, Pulver zur Herstellung eines Infusionslösungskonzentrates
Pulver zur Herstellung eines Infusionslösungskonzentrates
1
Official Swissmedic V2 data
Additional information from the official database
Official medical documents
Detailed composition
| Substance | Quantity | Type | Category |
|---|---|---|---|
|
PRC
|
160.0 MG | Substance | Wirkstoff (Principe actif) |
|
PRC
|
- | Substance | HNIDK |
|
PRC
|
- | Substance | HNIDK |
|
PRC
|
- | Substance | HNIDK |
|
PRC
|
2.07 MG | Substance | HBESI |
|
PRC
|
- | Substance | HNIDK |
Reimbursement information
Public price
CHF 2618.50
Specialties list
Yes
Generic
No
Reimbursement limitation
SL addition date:
01/01/2016
Authorization holder
Roche Pharma (Schweiz) AG
4058 Basel
Authorization information
- Swissmedic authorization number
- 62892
- Drug name
- Kadcyla, Pulver für ein Konzentrat zur Herstellung einer Infusionslösung
- Galenic form
- PULPI
- ATC Code
- L01FD03
- Authorization status
- Z
- Dispensation category
- A
- First authorization
- 02/05/2013
- Authorization expiration date
- 31/12/9999
- IT number
- 07.16.1.
- Domain
- Human medicine
Packaging details
- Description (FR)
- KADCYLA i.v. subst sèche 160 mg flac
- Description (DE)
- KADCYLA i.v. Trockensub 160 mg Durchstf
- Market launch
- 02/05/2013
- Narcotic (BTM)
- No